25 XP   0   0   10

Jeil Pharmaceutical Co Ltd
Buy, Hold or Sell?

Let's analyse Jeil Pharmaceutical Co Ltd together

PenkeI guess you are interested in Jeil Pharmaceutical Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Jeil Pharmaceutical Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Jeil Pharmaceutical Co Ltd

I send you an email if I find something interesting about Jeil Pharmaceutical Co Ltd.

Quick analysis of Jeil Pharmaceutical Co Ltd (30 sec.)










What can you expect buying and holding a share of Jeil Pharmaceutical Co Ltd? (30 sec.)

How much money do you get?

How much money do you get?
₩0.07
When do you have the money?
1 year
How often do you get paid?
71.4%

What is your share worth?

Current worth
₩10,776.65
Expected worth in 1 year
₩10,875.13
How sure are you?
57.1%

+ What do you gain per year?

Total Gains per Share
₩198.45
Return On Investment
1.2%

For what price can you sell your share?

Current Price per Share
₩16,500.00
Expected price per share
₩14,540 - ₩18,250
How sure are you?
50%

1. Valuation of Jeil Pharmaceutical Co Ltd (5 min.)




Live pricePrice per Share (EOD)

₩16,500.00

Intrinsic Value Per Share

₩11,001.00 - ₩13,587.26

Total Value Per Share

₩21,777.65 - ₩24,363.92

2. Growth of Jeil Pharmaceutical Co Ltd (5 min.)




Is Jeil Pharmaceutical Co Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$109.9m$110.6m$4.4m3.9%

How much money is Jeil Pharmaceutical Co Ltd making?

Current yearPrevious yearGrowGrow %
Making money$875.8k-$2.2m$3.1m361.6%
Net Profit Margin0.6%-1.8%--

How much money comes from the company's main activities?

3. Financial Health of Jeil Pharmaceutical Co Ltd (5 min.)




What can you expect buying and holding a share of Jeil Pharmaceutical Co Ltd? (5 min.)

Welcome investor! Jeil Pharmaceutical Co Ltd's management wants to use your money to grow the business. In return you get a share of Jeil Pharmaceutical Co Ltd.

What can you expect buying and holding a share of Jeil Pharmaceutical Co Ltd?

First you should know what it really means to hold a share of Jeil Pharmaceutical Co Ltd. And how you can make/lose money.

Speculation

The Price per Share of Jeil Pharmaceutical Co Ltd is ₩16,500. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Jeil Pharmaceutical Co Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Jeil Pharmaceutical Co Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩10,776.65. Based on the TTM, the Book Value Change Per Share is ₩24.62 per quarter. Based on the YOY, the Book Value Change Per Share is ₩-194.55 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩24.99 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Jeil Pharmaceutical Co Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.110.0%-0.110.0%-0.130.0%-0.090.0%-0.080.0%
Usd Book Value Change Per Share-0.310.0%0.020.0%-0.140.0%-0.070.0%0.360.0%
Usd Dividend Per Share0.000.0%0.020.0%0.040.0%0.030.0%0.030.0%
Usd Total Gains Per Share-0.310.0%0.030.0%-0.100.0%-0.040.0%0.390.0%
Usd Price Per Share11.97-12.40-15.13-22.18-22.68-
Price to Earnings Ratio-27.84--35.79--35.26-86.16-91.85-
Price-to-Total Gains Ratio-38.15--104.04--48.38-269.89-257.21-
Price to Book Ratio1.59-1.57-1.99-2.67-2.72-
Price-to-Total Gains Ratio-38.15--104.04--48.38-269.89-257.21-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share11.55
Number of shares86
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.020.03
Usd Book Value Change Per Share0.02-0.07
Usd Total Gains Per Share0.03-0.04
Gains per Quarter (86 shares)2.99-3.18
Gains per Year (86 shares)11.95-12.70
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
166210-23-23
212121421-46-36
318182631-69-49
424243841-92-62
530305052-115-75
636366262-138-88
742417472-161-101
848478683-184-114
954539893-207-127
106059110104-231-140

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%8.012.00.040.0%9.012.00.042.9%9.012.00.042.9%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%9.011.00.045.0%10.011.00.047.6%10.011.00.047.6%
Dividend per Share2.00.02.050.0%10.00.02.083.3%14.00.06.070.0%15.00.06.071.4%15.00.06.071.4%
Total Gains per Share1.03.00.025.0%5.07.00.041.7%11.09.00.055.0%12.09.00.057.1%12.09.00.057.1%

Fundamentals of Jeil Pharmaceutical Co Ltd

About Jeil Pharmaceutical Co Ltd

Jeil Pharmaceutical Co.,Ltd develops and supplies pharmaceutical products primarily in South Korea. It provides products in the areas of antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamine. The company also exports its products to approximately 40 countries in ASEAN, Central and South America, Africa, and internationally. Jeil Pharmaceutical Co.,Ltd was founded in 1959 and is headquartered in Seoul, South Korea.

Fundamental data was last updated by Penke on 2024-04-16 10:11:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is not making a profit/loss.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Jeil Pharmaceutical Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Jeil Pharmaceutical Co Ltd earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Jeil Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -1.2% means that ₩-0.01 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Jeil Pharmaceutical Co Ltd:

  • The MRQ is -1.2%. The company is making a loss. -1
  • The TTM is 0.6%. The company is not making a profit/loss.
Trends
Current periodCompared to+/- 
MRQ-1.2%TTM0.6%-1.8%
TTM0.6%YOY-1.8%+2.4%
TTM0.6%5Y-0.7%+1.3%
5Y-0.7%10Y-0.7%-0.1%
1.1.2. Return on Assets

Shows how efficient Jeil Pharmaceutical Co Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Jeil Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • -0.5% Return on Assets means that Jeil Pharmaceutical Co Ltd generated ₩0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Jeil Pharmaceutical Co Ltd:

  • The MRQ is -0.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is 0.3%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-0.5%TTM0.3%-0.7%
TTM0.3%YOY-0.7%+1.0%
TTM0.3%5Y-0.3%+0.6%
5Y-0.3%10Y-0.3%0.0%
1.1.3. Return on Equity

Shows how efficient Jeil Pharmaceutical Co Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Jeil Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • -1.4% Return on Equity means Jeil Pharmaceutical Co Ltd generated ₩-0.01 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Jeil Pharmaceutical Co Ltd:

  • The MRQ is -1.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is 0.7%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-1.4%TTM0.7%-2.1%
TTM0.7%YOY-2.0%+2.7%
TTM0.7%5Y-0.8%+1.5%
5Y-0.8%10Y-0.7%-0.1%

1.2. Operating Efficiency of Jeil Pharmaceutical Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Jeil Pharmaceutical Co Ltd is operating .

  • Measures how much profit Jeil Pharmaceutical Co Ltd makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Jeil Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Jeil Pharmaceutical Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.5%+0.5%
TTM-0.5%YOY-1.1%+0.7%
TTM-0.5%5Y0.1%-0.5%
5Y0.1%10Y0.2%-0.1%
1.2.2. Operating Ratio

Measures how efficient Jeil Pharmaceutical Co Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.76 means that the operating costs are ₩1.76 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Jeil Pharmaceutical Co Ltd:

  • The MRQ is 1.762. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.736. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.762TTM1.736+0.026
TTM1.736YOY1.802-0.066
TTM1.7365Y1.749-0.012
5Y1.74910Y1.748+0.000

1.3. Liquidity of Jeil Pharmaceutical Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Jeil Pharmaceutical Co Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.00 means the company has ₩1.00 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Jeil Pharmaceutical Co Ltd:

  • The MRQ is 0.996. The company is just not able to pay all its short-term debts. -1
  • The TTM is 1.053. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ0.996TTM1.053-0.056
TTM1.053YOY1.138-0.085
TTM1.0535Y1.231-0.178
5Y1.23110Y1.239-0.008
1.3.2. Quick Ratio

Measures if Jeil Pharmaceutical Co Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Jeil Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.48 means the company can pay off ₩0.48 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Jeil Pharmaceutical Co Ltd:

  • The MRQ is 0.483. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.510. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.483TTM0.510-0.028
TTM0.510YOY0.611-0.101
TTM0.5105Y0.657-0.147
5Y0.65710Y0.669-0.012

1.4. Solvency of Jeil Pharmaceutical Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Jeil Pharmaceutical Co Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Jeil Pharmaceutical Co Ltd to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.68 means that Jeil Pharmaceutical Co Ltd assets are financed with 67.8% credit (debt) and the remaining percentage (100% - 67.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Jeil Pharmaceutical Co Ltd:

  • The MRQ is 0.678. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.665. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.678TTM0.665+0.013
TTM0.665YOY0.638+0.026
TTM0.6655Y0.606+0.059
5Y0.60610Y0.603+0.003
1.4.2. Debt to Equity Ratio

Measures if Jeil Pharmaceutical Co Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Jeil Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 208.3% means that company has ₩2.08 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Jeil Pharmaceutical Co Ltd:

  • The MRQ is 2.083. The company is just not able to pay all its debts with equity.
  • The TTM is 1.977. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.083TTM1.977+0.106
TTM1.977YOY1.750+0.227
TTM1.9775Y1.570+0.407
5Y1.57010Y1.552+0.019

2. Market Valuation of Jeil Pharmaceutical Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Jeil Pharmaceutical Co Ltd generates.

  • Above 15 is considered overpriced but always compare Jeil Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -27.84 means the investor is paying ₩-27.84 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Jeil Pharmaceutical Co Ltd:

  • The EOD is -26.868. Based on the earnings, the company is expensive. -2
  • The MRQ is -27.845. Based on the earnings, the company is expensive. -2
  • The TTM is -35.791. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-26.868MRQ-27.845+0.977
MRQ-27.845TTM-35.791+7.946
TTM-35.791YOY-35.257-0.534
TTM-35.7915Y86.160-121.951
5Y86.16010Y91.853-5.693
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Jeil Pharmaceutical Co Ltd:

  • The EOD is 5.248. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 5.439. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 1.989. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD5.248MRQ5.439-0.191
MRQ5.439TTM1.989+3.450
TTM1.989YOY9.500-7.511
TTM1.9895Y5.845-3.856
5Y5.84510Y7.502-1.657
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Jeil Pharmaceutical Co Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 1.59 means the investor is paying ₩1.59 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Jeil Pharmaceutical Co Ltd:

  • The EOD is 1.531. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.587. Based on the equity, the company is underpriced. +1
  • The TTM is 1.568. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.531MRQ1.587-0.056
MRQ1.587TTM1.568+0.018
TTM1.568YOY1.988-0.420
TTM1.5685Y2.669-1.101
5Y2.66910Y2.717-0.048
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Jeil Pharmaceutical Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---448.24224.619-1921%-194.550-57%-95.744-79%513.174-187%
Book Value Per Share--10776.65211289.778-5%10847.358-1%11743.198-8%11788.356-9%
Current Ratio--0.9961.053-5%1.138-12%1.231-19%1.239-20%
Debt To Asset Ratio--0.6780.665+2%0.638+6%0.606+12%0.603+12%
Debt To Equity Ratio--2.0831.977+5%1.750+19%1.570+33%1.552+34%
Dividend Per Share---24.993-100%57.499-100%42.988-100%43.802-100%
Eps---153.529-155.222+1%-185.852+21%-123.784-19%-115.193-25%
Free Cash Flow Per Share--785.942-249.743+132%-550.849+170%-75.207+110%-57.979+107%
Free Cash Flow To Equity Per Share--785.942209.316+275%-150.677+119%173.513+353%153.317+413%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--13587.265--------
Intrinsic Value_10Y_min--11000.998--------
Intrinsic Value_1Y_max---449.002--------
Intrinsic Value_1Y_min---442.093--------
Intrinsic Value_3Y_max--30.774--------
Intrinsic Value_3Y_min--1.523--------
Intrinsic Value_5Y_max--2174.093--------
Intrinsic Value_5Y_min--1899.177--------
Market Cap240429750000.000-4%249172940700.000258097994862.500-3%315019292900.000-21%462552984650.000-46%472861504428.571-47%
Net Profit Margin---0.0120.006-314%-0.018+47%-0.007-42%-0.007-46%
Operating Margin----0.0050%-0.0110%0.001-100%0.002-100%
Operating Ratio--1.7621.736+1%1.802-2%1.749+1%1.748+1%
Pb Ratio1.531-4%1.5871.568+1%1.988-20%2.669-41%2.717-42%
Pe Ratio-26.868+4%-27.845-35.791+29%-35.257+27%86.160-132%91.853-130%
Price Per Share16500.000-4%17100.00017712.500-3%21612.500-21%31692.500-46%32402.381-47%
Price To Free Cash Flow Ratio5.248-4%5.4391.989+173%9.500-43%5.845-7%7.502-27%
Price To Total Gains Ratio-36.810+4%-38.149-104.036+173%-48.380+27%269.891-114%257.213-115%
Quick Ratio--0.4830.510-5%0.611-21%0.657-27%0.669-28%
Return On Assets---0.0050.003-270%-0.007+63%-0.003-37%-0.003-42%
Return On Equity---0.0140.007-304%-0.020+45%-0.008-46%-0.007-50%
Total Gains Per Share---448.24249.612-1003%-137.052-69%-52.755-88%556.976-180%
Usd Book Value--109922520.099115156437.982-5%110669364.045-1%119937475.648-8%120390652.109-9%
Usd Book Value Change Per Share---0.3140.017-1921%-0.136-57%-0.067-79%0.359-187%
Usd Book Value Per Share--7.5447.903-5%7.593-1%8.220-8%8.252-9%
Usd Dividend Per Share---0.017-100%0.040-100%0.030-100%0.031-100%
Usd Eps---0.107-0.109+1%-0.130+21%-0.087-19%-0.081-25%
Usd Free Cash Flow--8016656.753-2547394.304+132%-5618406.469+170%-767091.946+110%-591365.590+107%
Usd Free Cash Flow Per Share--0.550-0.175+132%-0.386+170%-0.053+110%-0.041+107%
Usd Free Cash Flow To Equity Per Share--0.5500.147+275%-0.105+119%0.121+353%0.107+413%
Usd Market Cap168300825.000-4%174421058.490180668596.404-3%220513505.030-21%323787089.255-46%331003053.100-47%
Usd Price Per Share11.550-4%11.97012.399-3%15.129-21%22.185-46%22.682-47%
Usd Profit---1566001.248875830.363-279%-2290906.499+46%-845541.378-46%-777770.629-50%
Usd Revenue--125767633.166127118907.655-1%126390236.7820%122921701.800+2%122550343.637+3%
Usd Total Gains Per Share---0.3140.035-1003%-0.096-69%-0.037-88%0.390-180%
 EOD+4 -4MRQTTM+9 -25YOY+16 -185Y+10 -2510Y+10 -25

3.2. Fundamental Score

Let's check the fundamental score of Jeil Pharmaceutical Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-26.868
Price to Book Ratio (EOD)Between0-11.531
Net Profit Margin (MRQ)Greater than0-0.012
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.483
Current Ratio (MRQ)Greater than10.996
Debt to Asset Ratio (MRQ)Less than10.678
Debt to Equity Ratio (MRQ)Less than12.083
Return on Equity (MRQ)Greater than0.15-0.014
Return on Assets (MRQ)Greater than0.05-0.005
Total1/10 (10.0%)

3.3. Technical Score

Let's check the technical score of Jeil Pharmaceutical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose16,540.000
Total1/1 (100.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Net Working Capital  22,983,65013,482,41436,466,064-28,139,0088,327,057-3,520,9924,806,065-5,930,600-1,124,535
Tax Provision  317,488-290,06827,421508,760536,181-419,478116,702-4,081,483-3,964,781



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in KRW. All numbers in thousands.

Summary
Total Assets487,326,298
Total Liabilities330,294,126
Total Stockholder Equity158,570,120
 As reported
Total Liabilities 330,294,126
Total Stockholder Equity+ 158,570,120
Total Assets = 487,326,298

Assets

Total Assets487,326,298
Total Current Assets317,045,923
Long-term Assets170,280,375
Total Current Assets
Cash And Cash Equivalents 32,990,886
Short-term Investments 2,666,657
Net Receivables 150,954,766
Inventory 109,768,045
Other Current Assets 4,025,783
Total Current Assets  (as reported)317,045,923
Total Current Assets  (calculated)300,406,137
+/- 16,639,785
Long-term Assets
Property Plant Equipment 137,040,757
Intangible Assets 12,880,971
Long-term Assets Other 0
Long-term Assets  (as reported)170,280,375
Long-term Assets  (calculated)149,921,728
+/- 20,358,647

Liabilities & Shareholders' Equity

Total Current Liabilities318,170,458
Long-term Liabilities12,123,668
Total Stockholder Equity158,570,120
Total Current Liabilities
Short Long Term Debt 64,771,976
Accounts payable 144,338,120
Other Current Liabilities 14,735,749
Total Current Liabilities  (as reported)318,170,458
Total Current Liabilities  (calculated)223,845,845
+/- 94,324,613
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt6,398,302
Long-term Liabilities Other 0
Long-term Liabilities  (as reported)12,123,668
Long-term Liabilities  (calculated)6,398,302
+/- 5,725,366
Total Stockholder Equity
Total Stockholder Equity (as reported)158,570,120
Total Stockholder Equity (calculated)0
+/- 158,570,120
Other
Capital Stock7,352,436
Common Stock Shares Outstanding 14,572
Net Debt 31,781,090
Net Invested Capital 223,342,096
Net Working Capital -1,124,535
Property Plant and Equipment Gross 275,728,765



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
> Total Assets 
402,903,123
414,644,572
415,351,870
401,587,464
401,585,119
410,443,309
418,090,157
418,092,729
409,663,297
441,117,837
441,549,794
441,753,633
426,486,418
426,451,051
430,801,628
436,461,334
456,891,539
483,263,494
488,925,073
504,298,427
487,326,298
487,326,298504,298,427488,925,073483,263,494456,891,539436,461,334430,801,628426,451,051426,486,418441,753,633441,549,794441,117,837409,663,297418,092,729418,090,157410,443,309401,585,119401,587,464415,351,870414,644,572402,903,123
   > Total Current Assets 
273,355,962
285,942,733
282,962,219
270,395,114
264,134,194
274,160,991
283,908,650
285,460,019
277,512,818
308,653,381
308,316,221
309,191,312
284,672,326
285,461,693
290,456,009
285,450,642
291,640,788
317,803,732
323,081,519
339,746,048
317,045,923
317,045,923339,746,048323,081,519317,803,732291,640,788285,450,642290,456,009285,461,693284,672,326309,191,312308,316,221308,653,381277,512,818285,460,019283,908,650274,160,991264,134,194270,395,114282,962,219285,942,733273,355,962
       Cash And Cash Equivalents 
2,495,340
15,391,504
23,382,039
16,217,655
13,515,271
8,298,395
5,442,207
3,053,409
3,893,474
26,902,573
26,318,083
35,720,764
25,963,279
27,680,186
14,009,188
16,874,158
31,446,234
25,452,079
36,312,548
27,065,298
32,990,886
32,990,88627,065,29836,312,54825,452,07931,446,23416,874,15814,009,18827,680,18625,963,27935,720,76426,318,08326,902,5733,893,4743,053,4095,442,2078,298,39513,515,27116,217,65523,382,03915,391,5042,495,340
       Short-term Investments 
0
0
1,832,039
1,832,039
4,762
18,449
9,464
9,465
2,694,588
2,698,301
2,841,416
2,766,508
2,040,062
1,647,419
1,644,039
1,651,661
142,458
142,458
9,308,420
9,334,220
2,666,657
2,666,6579,334,2209,308,420142,458142,4581,651,6611,644,0391,647,4192,040,0622,766,5082,841,4162,698,3012,694,5889,4659,46418,4494,7621,832,0391,832,03900
       Net Receivables 
176,114,463
150,652,207
151,667,332
146,962,207
141,516,503
144,676,235
167,212,545
161,941,904
156,922,345
164,299,716
166,789,500
160,519,765
146,688,938
150,585,502
167,690,306
157,488,898
137,807,454
153,376,571
151,928,906
151,104,365
150,954,766
150,954,766151,104,365151,928,906153,376,571137,807,454157,488,898167,690,306150,585,502146,688,938160,519,765166,789,500164,299,716156,922,345161,941,904167,212,545144,676,235141,516,503146,962,207151,667,332150,652,207176,114,463
       Inventory 
88,446,066
91,716,232
82,796,817
80,079,354
84,071,452
97,763,186
106,164,506
114,226,311
109,310,619
108,592,845
107,653,878
102,741,294
102,457,666
97,204,198
100,535,242
101,223,281
99,150,809
116,040,368
115,720,005
125,987,306
109,768,045
109,768,045125,987,306115,720,005116,040,36899,150,809101,223,281100,535,24297,204,198102,457,666102,741,294107,653,878108,592,845109,310,619114,226,311106,164,50697,763,18684,071,45280,079,35482,796,81791,716,23288,446,066
       Other Current Assets 
6,174,938
6,786,558
0
0
4,217,438
0
5,044,738
6,081,743
4,523,917
6,061,768
4,674,986
7,276,050
7,335,671
7,875,632
6,306,591
7,938,657
4,531,478
4,311,639
9,433,346
4,672,539
4,025,783
4,025,7834,672,5399,433,3464,311,6394,531,4787,938,6576,306,5917,875,6327,335,6717,276,0504,674,9866,061,7684,523,9176,081,7435,044,73804,217,438006,786,5586,174,938
   > Long-term Assets 
0
128,701,839
132,389,651
131,192,350
137,450,925
136,282,318
134,181,507
132,632,709
132,150,480
132,464,456
133,233,573
132,562,321
141,814,092
140,989,358
140,345,619
151,010,692
165,250,752
165,459,761
165,843,554
164,552,378
170,280,375
170,280,375164,552,378165,843,554165,459,761165,250,752151,010,692140,345,619140,989,358141,814,092132,562,321133,233,573132,464,456132,150,480132,632,709134,181,507136,282,318137,450,925131,192,350132,389,651128,701,8390
       Property Plant Equipment 
120,481,184
119,418,502
115,890,085
115,293,004
121,614,302
120,981,294
118,731,682
116,885,130
115,547,198
114,343,256
114,684,816
114,626,911
125,709,643
125,441,811
124,663,654
128,141,686
138,402,417
138,564,646
137,934,344
136,545,154
137,040,757
137,040,757136,545,154137,934,344138,564,646138,402,417128,141,686124,663,654125,441,811125,709,643114,626,911114,684,816114,343,256115,547,198116,885,130118,731,682120,981,294121,614,302115,293,004115,890,085119,418,502120,481,184
       Long Term Investments 
977,948
1,156,184
1,159,185
962,660
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000962,6601,159,1851,156,184977,948
       Intangible Assets 
4,359,053
4,395,309
4,370,410
4,355,152
4,323,894
4,281,287
4,439,583
4,401,596
4,095,369
4,034,337
3,880,013
3,818,415
3,762,338
3,711,730
3,731,786
8,474,859
9,381,751
10,646,874
11,669,819
12,621,288
12,880,971
12,880,97112,621,28811,669,81910,646,8749,381,7518,474,8593,731,7863,711,7303,762,3383,818,4153,880,0134,034,3374,095,3694,401,5964,439,5834,281,2874,323,8944,355,1524,370,4104,395,3094,359,053
       Long-term Assets Other 
0
1
0
131,192,350
0
136,282,318
0
0
-1
0
0
0
1
0
0
0
0
0
-1
0
0
00-1000001000-100136,282,3180131,192,350010
> Total Liabilities 
217,968,578
230,256,171
230,155,019
215,264,612
231,540,836
237,597,918
244,047,351
243,587,519
237,184,010
258,791,620
257,738,493
258,711,567
259,139,220
264,843,662
271,058,987
281,012,217
301,294,320
313,778,122
320,969,569
340,734,686
330,294,126
330,294,126340,734,686320,969,569313,778,122301,294,320281,012,217271,058,987264,843,662259,139,220258,711,567257,738,493258,791,620237,184,010243,587,519244,047,351237,597,918231,540,836215,264,612230,155,019230,256,171217,968,578
   > Total Current Liabilities 
194,556,097
206,851,267
207,225,114
192,678,687
208,519,278
214,827,767
222,030,117
222,308,320
218,058,270
224,758,228
230,137,623
232,285,400
221,943,181
227,623,001
256,120,943
264,561,219
268,657,137
281,337,668
301,870,997
334,939,984
318,170,458
318,170,458334,939,984301,870,997281,337,668268,657,137264,561,219256,120,943227,623,001221,943,181232,285,400230,137,623224,758,228218,058,270222,308,320222,030,117214,827,767208,519,278192,678,687207,225,114206,851,267194,556,097
       Short-term Debt 
5,593,750
17,625,000
18,656,250
17,125,000
12,125,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000012,125,00017,125,00018,656,25017,625,0005,593,750
       Short Long Term Debt 
5,593,750
17,625,000
18,656,250
17,125,000
12,125,000
12,125,000
27,125,000
36,128,745
36,544,203
34,703,735
30,073,587
32,636,009
30,290,975
30,187,131
31,860,929
44,810,717
43,075,736
51,693,638
66,269,870
76,041,280
64,771,976
64,771,97676,041,28066,269,87051,693,63843,075,73644,810,71731,860,92930,187,13130,290,97532,636,00930,073,58734,703,73536,544,20336,128,74527,125,00012,125,00012,125,00017,125,00018,656,25017,625,0005,593,750
       Accounts payable 
144,752,774
156,662,172
154,087,624
142,229,316
149,575,963
165,311,180
157,631,868
147,598,880
143,363,086
150,534,358
156,402,589
156,898,320
153,084,038
158,130,767
164,422,266
158,411,367
151,641,431
153,491,209
145,880,994
158,541,404
144,338,120
144,338,120158,541,404145,880,994153,491,209151,641,431158,411,367164,422,266158,130,767153,084,038156,898,320156,402,589150,534,358143,363,086147,598,880157,631,868165,311,180149,575,963142,229,316154,087,624156,662,172144,752,774
       Other Current Liabilities 
31,813,178
32,209,800
-1
0
12,676,784
0
35,489,733
36,848,958
36,528,489
37,743,385
41,889,263
40,814,119
36,624,015
37,322,463
57,872,005
59,662,698
14,297,183
14,426,107
87,823,741
15,332,117
14,735,749
14,735,74915,332,11787,823,74114,426,10714,297,18359,662,69857,872,00537,322,46336,624,01540,814,11941,889,26337,743,38536,528,48936,848,95835,489,733012,676,7840-132,209,80031,813,178
   > Long-term Liabilities 
0
23,404,905
22,929,905
22,585,926
23,021,557
22,770,151
22,017,234
21,279,198
19,125,740
34,033,392
27,600,870
26,426,167
37,196,039
37,220,661
7,088,607
8,383,600
32,637,182
32,440,454
6,215,107
5,794,702
12,123,668
12,123,6685,794,7026,215,10732,440,45432,637,1828,383,6007,088,60737,220,66137,196,03926,426,16727,600,87034,033,39219,125,74021,279,19822,017,23422,770,15123,021,55722,585,92622,929,90523,404,9050
       Capital Lease Obligations 
0
364,828
711,676
980,517
6,517,357
6,172,119
5,912,240
5,495,006
5,103,875
5,211,158
4,919,220
4,836,180
8,532,195
8,189,815
7,797,915
7,739,753
7,274,852
6,821,466
7,025,400
6,563,910
6,398,302
6,398,3026,563,9107,025,4006,821,4667,274,8527,739,7537,797,9158,189,8158,532,1954,836,1804,919,2205,211,1585,103,8755,495,0065,912,2406,172,1196,517,357980,517711,676364,8280
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
1
0
0
0
1
0
0
0
0
0
0
0
0
000000001000100000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,532,099
0
0
7,133,817
0
0
007,133,817004,532,099000000000000000
> Total Stockholder Equity
184,934,545
184,388,401
185,196,851
186,322,852
170,044,284
172,845,391
174,042,806
174,474,365
172,394,244
176,130,134
176,532,180
176,098,449
168,213,360
162,947,314
161,186,145
157,381,757
157,909,021
169,882,972
168,533,470
164,422,335
158,570,120
158,570,120164,422,335168,533,470169,882,972157,909,021157,381,757161,186,145162,947,314168,213,360176,098,449176,532,180176,130,134172,394,244174,474,365174,042,806172,845,391170,044,284186,322,852185,196,851184,388,401184,934,545
   Common Stock
7,352,436
7,352,436
7,352,436
7,352,436
7,352,436
7,352,436
7,352,436
7,352,436
7,352,436
7,352,436
7,352,436
7,352,436
7,352,436
7,352,436
7,352,436
7,352,436
0
0
7,352,436
0
0
007,352,436007,352,4367,352,4367,352,4367,352,4367,352,4367,352,4367,352,4367,352,4367,352,4367,352,4367,352,4367,352,4367,352,4367,352,4367,352,4367,352,436
   Retained Earnings 
18,924,064
18,377,919
20,354,331
21,480,332
5,216,066
7,914,872
4,008,119
4,676,874
2,840,808
502,519
1,249,457
894,289
-10,413,554
-15,282,617
-17,043,786
-20,848,174
-20,320,910
-8,346,960
-9,696,461
-13,807,596
-19,659,811
-19,659,811-13,807,596-9,696,461-8,346,960-20,320,910-20,848,174-17,043,786-15,282,617-10,413,554894,2891,249,457502,5192,840,8084,676,8744,008,1197,914,8725,216,06621,480,33220,354,33118,377,91918,924,064
   Capital Surplus 000000000000000000000
   Treasury Stock000000000000000000000
   Other Stockholders Equity 
9,854,716
9,854,716
9,854,716
9,854,716
11,506,612
11,506,612
16,874,160
16,635,327
16,706,152
16,600,653
16,255,762
16,255,761
20,409,975
20,409,975
20,409,975
20,409,975
0
0
20,409,975
0
0
0020,409,9750020,409,97520,409,97520,409,97520,409,97516,255,76116,255,76216,600,65316,706,15216,635,32716,874,16011,506,61211,506,6129,854,7169,854,7169,854,7169,854,716



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue726,393,758
Cost of Revenue-542,137,866
Gross Profit184,255,893184,255,893
 
Operating Income (+$)
Gross Profit184,255,893
Operating Expense-717,505,810
Operating Income8,887,949-533,249,917
 
Operating Expense (+$)
Research Development45,727,389
Selling General Administrative76,481,557
Selling And Marketing Expenses0
Operating Expense717,505,810122,208,946
 
Net Interest Income (+$)
Interest Income1,030,572
Interest Expense-6,033,022
Other Finance Cost-0
Net Interest Income-5,002,450
 
Pretax Income (+$)
Operating Income8,887,949
Net Interest Income-5,002,450
Other Non-Operating Income Expenses0
Income Before Tax (EBT)1,916,0938,887,949
EBIT - interestExpense = -6,033,022
5,004,745
11,037,767
Interest Expense6,033,022
Earnings Before Interest and Taxes (EBIT)07,949,115
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax1,916,093
Tax Provision--3,284,477
Net Income From Continuing Ops5,200,5705,200,570
Net Income5,004,745
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net05,002,450
 

Technical Analysis of Jeil Pharmaceutical Co Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Jeil Pharmaceutical Co Ltd. The general trend of Jeil Pharmaceutical Co Ltd is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Jeil Pharmaceutical Co Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Jeil Pharmaceutical Co Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 18,010 < 18,120 < 18,250.

The bearish price targets are: 15,500 > 15,300 > 14,540.

Tweet this
Jeil Pharmaceutical Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Jeil Pharmaceutical Co Ltd. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Jeil Pharmaceutical Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Jeil Pharmaceutical Co Ltd.

Jeil Pharmaceutical Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartJeil Pharmaceutical Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Jeil Pharmaceutical Co Ltd. The current adx is .

Jeil Pharmaceutical Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Jeil Pharmaceutical Co Ltd.

Jeil Pharmaceutical Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Jeil Pharmaceutical Co Ltd.

Jeil Pharmaceutical Co Ltd Daily Relative Strength Index (RSI) ChartJeil Pharmaceutical Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Jeil Pharmaceutical Co Ltd.

Jeil Pharmaceutical Co Ltd Daily Stochastic Oscillator ChartJeil Pharmaceutical Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Jeil Pharmaceutical Co Ltd.

Jeil Pharmaceutical Co Ltd Daily Commodity Channel Index (CCI) ChartJeil Pharmaceutical Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Jeil Pharmaceutical Co Ltd.

Jeil Pharmaceutical Co Ltd Daily Chande Momentum Oscillator (CMO) ChartJeil Pharmaceutical Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Jeil Pharmaceutical Co Ltd.

Jeil Pharmaceutical Co Ltd Daily Williams %R ChartJeil Pharmaceutical Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Jeil Pharmaceutical Co Ltd.

Jeil Pharmaceutical Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Jeil Pharmaceutical Co Ltd.

Jeil Pharmaceutical Co Ltd Daily Average True Range (ATR) ChartJeil Pharmaceutical Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Jeil Pharmaceutical Co Ltd.

Jeil Pharmaceutical Co Ltd Daily On-Balance Volume (OBV) ChartJeil Pharmaceutical Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Jeil Pharmaceutical Co Ltd.

Jeil Pharmaceutical Co Ltd Daily Money Flow Index (MFI) ChartJeil Pharmaceutical Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Jeil Pharmaceutical Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-02ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-04BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Jeil Pharmaceutical Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Jeil Pharmaceutical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose16,540.000
Total1/1 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Jeil Pharmaceutical Co Ltd with someone you think should read this too:
  • Are you bullish or bearish on Jeil Pharmaceutical Co Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Jeil Pharmaceutical Co Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Jeil Pharmaceutical Co Ltd

I send you an email if I find something interesting about Jeil Pharmaceutical Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Jeil Pharmaceutical Co Ltd.

Receive notifications about Jeil Pharmaceutical Co Ltd in your mailbox!